Your Perfect Partner

By Carolyn Berg and Carla Vozone

Interest and investment in dry powder inhalation (DPI) technology are rapidly increasing, solidifying its growing popularity in the field of inhalation drug delivery. This trend reflects a shift toward innovative, patient-friendly solutions for pulmonary and systemic therapies. A recent review of data from clinicaltrials.gov reveals that a substantial number of studies now employ dry powder inhalers (DPIs) as a preferred route of drug administration. These studies span various stages of development, from early recruitment to active execution, with a significant portion already completed, further demonstrating the momentum behind this technology.

The rising adoption of DPIs underscores their potential as an efficient and effective method for delivering medication directly to the lungs. Advantages such as ease of use, elimination of propellants, improved chemical stability, and the ability to accommodate a wide range of formulations have bolstered confidence in inhalable dry powders. This growing interest highlights their versatility, with applications in areas such as respiratory diseases, vaccines, and systemic therapies, positioning DPIs as a key driver of innovation in drug delivery systems.